Patients with Idiopathic Pulmonary Fibrosis with Antibodies to Heat Shock Protein 70 Have Poor Prognoses
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Rationale: Diverse autoantibodies are present in most patients with idiopathic pulmonary fibrosis (IPF). We hypothesized that specific autoantibodies may associate with IPF manifestations. Objectives: To identify clinically relevant, antigen-specific immune responses in patients with IPF. Methods: Autoantibodies were detected by immunoblots and ELISA. Intrapulmonary immune processes were evaluated by immunohistochemistry. Anti–heat shock protein 70 (HSP70) IgG was isolated from plasma by immunoaffinity. Flow cytometry was used for leukocyte functional studies. Measurements and Main Results: HSP70 was identified as a potential IPF autoantigen in discovery assays. Anti-HSP70 IgG autoantibodies were detected by immunoblots in 3% of 60 control subjects versus 25% of a cross-sectional IPF cohort (n = 122) (P = 0.0004), one-half the patients with IPF who died (P = 0.008), and 70% of those with acute exacerbations (P = 0.0005). Anti-HSP70 autoantibodies in patients with IPF were significantly associated with HLA allele biases, greater subsequent FVC reductions (P = 0.0004), and lesser 1-year survival (40 ± 10% vs. 80 ± 5%; hazard ratio = 4.2; 95% confidence interval, 2.0–8.6; P < 0.0001). HSP70 protein, antigen–antibody complexes, and complement were prevalent in IPF lungs. HSP70 protein was an autoantigen for IPF CD4 T cells, inducing lymphocyte proliferation (P = 0.004) and IL-4 production (P = 0.01). IPF anti-HSP70 autoantibodies activated monocytes (P = 0.009) and increased monocyte IL-8 production (P = 0.049). ELISA confirmed the association between anti-HSP70 autoreactivity and IPF outcome. Anti-HSP70 autoantibodies were also found in patients with other interstitial lung diseases but were not associated with their clinical progression. Conclusions: Patients with IPF with anti-HSP70 autoantibodies have more near-term lung function deterioration and mortality. These findings suggest antigen-specific immunoassays could provide useful clinical information in individual patients with IPF and may have implications for understanding IPF progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar findings were observed with the presence of anti-HSP70 autoantibodies in patients with IPF (166).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765 · cited 1×
“Antigen(or autoantigen-) activated T cells can cause severe injuries, both directly and/or by production of mediators that activate and recruit other leukocyte, epithelial, and mesenchymal effectors, and these lymphocytes are implicated as the initiation of many diseaseassociated inflammatory cascades (28, 29, 41, 42).”
BackgroundAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationZuo, F., Kaminski, N., Eugui, E., Allard, J., Yakhini, Z., Ben-Dor, A., Lollini, L., Morris, D., Kim, Y., DeLustro, B., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092134099 · Cited by 620
Self-citationAutoimmune disease: why and where it occurs
Marrack, P., Kappler, J., & Kotzin, B. L. (2001) · Nature Medicine · doi:10.1038/90935 · Cited by 609 · cited 4×
“Antigen(or autoantigen-) activated T cells can cause severe injuries, both directly and/or by production of mediators that activate and recruit other leukocyte, epithelial, and mesenchymal effectors, and these lymphocytes are implicated as the initiation of many diseaseassociated inflammatory cascades (28, 29, 41, 42).”
BackgroundInfluentialEvidence‐based guidelines for the use of immunologic tests: Antinuclear antibody testing
Solomon, D. H., Kavanaugh, A. J., Schur, P. H., & American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines (2002) · Arthritis Care & Research · doi:10.1002/art.10561 · Cited by 510
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis
Richards, T. J., Kaminski, N., Baribaud, F., Flavin, S., Brodmerkel, C., Horowitz, D., Li, K., Choi, J., Vuga, L. J., Lindell, K. O., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0058oc · Cited by 381 · cited 1×
“IL-8 expression is a correlate (and possible mediator) of IPF pathogenesis (36).”
BackgroundSelf-citationThe clinical relevance of autoantibodies in scleroderma.
Ho, K. T., & Reveille, J. D. (2003) · Arthritis Research · doi:10.1186/ar628 · Cited by 337
Franks, A. L., & Slansky, J. E. (2012) · PubMed · Cited by 326
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Cancro, M. P., D’Cruz, D. P., & Khamashta, M. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38010 · Cited by 283
Autoantibodies in Patients with Chronic Obstructive Pulmonary Disease
Feghali-Bostwick, C. A., Gadgil, A. S., Otterbein, L. E., Pilewski, J. M., Stoner, M. W., Csizmadia, E., Zhang, Y., Sciurba, F. C., & Duncan, S. R. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-014oc · Cited by 269
Self-citationGlobal impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis
Kotsianidis, I., Nakou, E., Bouchliou, I., Tzouvelekis, A., Spanoudakis, E., Steiropoulos, P., Sotiriou, I., Aidinis, V., Margaritis, D., Tsatalas, C., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200812-1936oc · Cited by 230
Rituximab treatment of the anti-synthetase syndrome—a retrospective case series
Sem, M., Molberg, Ø., Lund, M. B., & Gran, J. T. (2009) · Rheumatology · doi:10.1093/rheumatology/kep157 · Cited by 218
Mechanisms of Immune Complex–Mediated Neutrophil Recruitment and Tissue Injury
Mayadas, T. N., Tsokos, G. C., & Tsuboi, N. (2009) · Circulation · doi:10.1161/circulationaha.108.771170 · Cited by 208
Gilani, S. R., Vuga, L. J., Lindell, K. O., Gibson, K. F., Xue, J., Kaminski, N., Valentine, V. G., Lindsay, E. K., George, M. P., Steele, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008959 · Cited by 203 · cited 4×
“Intracellular IFN-g and IL-4 production was quantified by flow cytometry (6, 24).”
BackgroundMethodInfluentialSelf-citationBoon, K., Bailey, N. W., Yang, J., Steel, M. P., Groshong, S., Kervitsky, D., Brown, K. K., Schwarz, M. I., & Schwartz, D. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005134 · Cited by 183
Marchal-Sommé, J., Uzunhan, Y., Marchand-Adam, S., Valeyre, D., Soumelis, V., Crestani, B., & Soler, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.5735 · Cited by 179
El Mezayen, R., El Gazzar, M., Seeds, M. C., McCall, C. E., Dreskin, S. C., & Nicolls, M. R. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.04.011 · Cited by 178
Cellular and Humoral Autoreactivity in Idiopathic Pulmonary Fibrosis
Feghali-Bostwick, C. A., Tsai, C. G., Valentine, V. G., Kantrow, S., Stoner, M. W., Pilewski, J. M., Gadgil, A., George, M. P., Gibson, K. F., Choi, A. M. K., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2592 · Cited by 160
Self-citationWisniewska, M., Karlberg, T., Lehtiö, L., Johansson, I., Kotenyova, T., Moche, M., & Schuler, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008625 · Cited by 158
Richards, T. J., Eggebeen, A., Gibson, K., Yousem, S., Fuhrman, C., Gochuico, B. R., Fertig, N., Oddis, C. V., Kaminski, N., Rosas, I. O., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24631 · Cited by 158
Self-citationMonaco, C., Andreakos, E., Kiriakidis, S., Feldmann, M., & Paleolog, E. (2004) · Current Drug Target -Inflammation & Allergy · doi:10.2174/1568010043483881 · Cited by 138
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy
Keir, G. J., Maher, T. M., Hansell, D. M., Denton, C. P., Ong, V. H., Singh, S., Wells, A. U., & Renzoni, E. A. (2012) · European Respiratory Journal · doi:10.1183/09031936.00163911 · Cited by 138
Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis
Taillé, C., Grootenboer-Mignot, S., Boursier, C., Michel, L., Debray, M.-P., Fagart, J., Barrientos, L., Mailleux, A., Cigna, N., Tubach, F., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0076oc · Cited by 120
Lu, M., Lai, N., Yu, H., Huang, H., Hsieh, S., & Yu, C. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27386 · Cited by 118
Kurosu, K., Takiguchi, Y., Okada, O., Yumoto, N., Sakao, S., Tada, Y., Kasahara, Y., Tanabe, N., Tatsumi, K., Weiden, M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.756 · Cited by 111
Idiopathic Pulmonary Fibrosis Related to Endothelial Injury and Antiendothelial Cell Antibodies
MAGRO, C. M. J., Waldman, W. J., Knight, D. A., Allen, J. N., Nádasdy, T., Frambach, G. E., Ross, P., & Marsh, C. B. (2006) · Human Immunology · doi:10.1016/j.humimm.2006.02.026 · Cited by 100
Reveille, J. D. (2003) · Current Rheumatology Reports · doi:10.1007/s11926-003-0045-1 · Cited by 86
Jang, J. Y., Jeong, J., Jun, H. R., Lee, S. C., Kim, J. S., Kim, Y., & Kwon, M. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-9179-2 · Cited by 82
Infections and Autoimmunity: A Panorama
Pordeus, V., Szyper-Kravitz, M., Levy, R. A., Vaz, N. M., & Shoenfeld, Y. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8048-8 · Cited by 73
Campbell, D. A., Poulter, L. W., Janossy, G., & du Bois, R. M. (1985) · Thorax · doi:10.1136/thx.40.6.405 · Cited by 72
Fu, S. M., Deshmukh, U. S., & Gaskin, F. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.05.004 · Cited by 72
T Cells and autoantibodies to human HSP70 in Type 1 diabetes in children
Abulafia-Lapid, R., Gillis, D., Yosef, O., Atlan, H., & Cohen, I. R. (2003) · Journal of Autoimmunity · doi:10.1016/s0896-8411(03)00038-6 · Cited by 69
Dobashi, N., Fujita, J., Murota, M., OHTSUKI, Y., Yamadori, I., Yoshinouchi, T., UEDA, R., Bandoh, S., Kamei, T., Nishioka, M., et al. (2000) · Lung · doi:10.1007/s004080000020 · Cited by 66
Autoimmunological features in inflammatory cardiomyopathy
Kallwellis-Opara, A., Dörner, A., Poller, W. C., Noutsias, M., Kühl, U., Schultheiß, H., & Pauschinger, M. (2007) · Clinical Research in Cardiology · doi:10.1007/s00392-007-0524-x · Cited by 63
YANG, Y., FUJITA, J., BANDOH, S., OHTSUKI, Y., YAMADORI, I., YOSHINOUCHI, T., & ISHIDA, T. (2002) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2002.01811.x · Cited by 62
Acute Cellular Rejection and Humoral Sensitization in Lung Transplant Recipients
Martinu, T., Howell, D. N., & Palmer, S. M. (2010) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0030-1249113 · Cited by 59
The HLA Class II Allele DRB1*1501 Is Over-Represented in Patients with Idiopathic Pulmonary Fibrosis
Xue, J., Gochuico, B. R., Alawad, A. S., Feghali-Bostwick, C. A., Noth, I., Nathan, S. D., Rosen, G. D., Rosas, I. O., Dacic, S., Ocak, I., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014715 · Cited by 58
Self-citationAssociation of stress proteins with autoantigens: a possible mechanism for triggering autoimmunity?
Purcell, A. W., Todd, A., Kinoshita, G., LYNCH, T. A., Keech, C. L., Gething, M. J., & Gordon, T. P. (2003) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2003.02153.x · Cited by 57
Yokota, S. (2006) · International Immunology · doi:10.1093/intimm/dxh399 · Cited by 55
Study of Immune Complexes in Bronchoalveolar Lavage Fluids
Dall’Aglio, P. P., Pesci, A., Bertorelli, G., Brianti, E., & Scarpa, S. (1988) · Respiration · doi:10.1159/000195495 · Cited by 48
Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis.
Ogushi, F., Tani, K., Endo, T., Tada, H., Kawano, T., Asano, T., Huang, L., Ohmoto, Y., Muraguchi, M., Moriguchi, H., et al. (2001) · PubMed · Cited by 43
Use of Combined Plasmapheresis and Immunosuppression in the Treatment of Goodpasture’s Syndrome
Erickson, S. B., Kurtz, S. B., Donadío, J. V., Holley, K. E., Wilson, C. B., & Pineda, A. A. (1979) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)19154-4 · Cited by 42
4. Autoimmunity, vasculitis, and autoantibodies
Lee, S. J., & Kavanaugh, A. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.06.023 · Cited by 25
Mapping of topoisomerase II α epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis
Grigolo, B., Mazzetti, I., Borzı̀, R. M., Hickson, I. D., Fabbri, M., Fasano, L., Melicòni, R., & Facchini, A. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00747.x · Cited by 24
Yokota, S., Chiba, S., Furuyama, H., & Fujii, N. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.10.009 · Cited by 23
Wallace, W. A., & Howie, S. (2001) · The Journal of Pathology · doi:10.1002/path.916 · Cited by 21
Perspective: Clues, not conclusions
Duncan, S. R. (2012) · Nature · doi:10.1038/489s15a · Cited by 5
Self-citation
Research works printed but not linked: 1
- Xue JM, Kahloon RA, Bhargava A, Banga G, Gochuico BR, Dacic S, Gibson KF, Kaminski N, Sciurba FC, Rosas IO, et al. Decreased survival of idiopathic pulmonary fibrosis patients with heat shock protein 70 autoreactivity [abstract]. Am J Respir Crit Care Med 2011;183:A4275 [Google Scholar]
Cited by
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citationMartinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Inflammation and immunity in IPF pathogenesis and treatment
Heukels, P., Moor, C. C., von der Thüsen, J. H., Wijsenbeek, M. S., & Kool, M. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.12.015 · Cited by 517
Selman, M., & Pardo, A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201312-2221pp · Cited by 454
Metadata
- Authors
- Kahloon, R. A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D. J., Bon, J., Soejima, M., Levesque, M. C., Lindell, K. O., Gibson, K. F., Kaminski, N., Banga, G., Oddis, C. V., Pilewski, J. M., Sciurba, F. C., Donahoe, M., Zhang, Y., & Duncan, S. R.
- Affiliations
- University of Pittsburgh (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Duncan, Steven R.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-01
- Volume
- 187
- Issue
- 7
- Pages
- 768-775
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC3678112
- OpenAlex
- W2142374046
- Cited by
- 190
- References
- 48
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 6 · 2023: 8 · 2022: 13 · 2021: 13 · 2020: 14 · 2019: 17 · 2018: 22 · 2017: 19 · 2016: 12 · 2015: 16 · 2014: 16 · 2013: 18
- FWCI
- 12.89
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50hl084932-05, UL1TR000005, HL084948)
- National Heart, Lung, and Blood Institute (K08HL083085, HL084948, HL007563, HL084932, P50-HL-084932, P50HL107172, U01HL112711, P50HL084948, HL107172, HL112711, T32HL007563)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- idiopathic pulmonary fibrosis, HSP70, autoantigens, prognosis, survival, lung function decline, acute exacerbation, CD4+ T cells, monocytes, interleukin-8, IL-4, complement system, interstitial lung disease, autoimmunity
- MeSH terms
- Aged, Antigen-Antibody Complex, Autoantibodies, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoglobulin G, Immunohistochemistry, Lung, Male, Prognosis, Interleukin-4, Linear Models, Proportional Hazards Models, Interleukin-8, HSP70 Heat-Shock Proteins, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.